Geoff Lindeman – Searching for novel therapeutic targets for the treatment and prevention of breast cancer
- Speaker: Geoff Lindeman, Joint Head, Cancer Biology and Stem Cells Division at The Walter and Eliza Hall Institute of Medical Research
- Talk title: Searching for novel therapeutic targets for the treatment and prevention of breast cancer
- Date & time: Friday, 7th May, 2021
- Host: Judith Balmaña, Head of VHIO’s Hereditary Cancer Genetics Group
His laboratory is studying molecular regulators of normal breast development and cancer, with a particular interest in understanding how mammary stem cells and their progeny contribute to the mammary epithelial cell hierarchy. Using this approach, it should be possible to decipher the molecular and cellular events that lead to breast cancer.
Their work led to the discovery of RANK-positive progenitors as a target for breast cancer prevention in BRCA1 mutation carriers, now being studied in an international phase 3 breast cancer prevention trial, BRCA-P.
Geoff Lindeman’s laboratory also uses patient derived xenograft (PDX) and organoid models to test promising anti-cancer agents. Pre-clinical studies on BH3 mimetics (which target survival pathways in tumour cells) has led to early phase studies of the BCL-2 inhibitor venetoclax in breast cancer.